DAWN 250117 15.00C (DAWN250117C15000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

DAWN250117C15000

Watchlist

0.15
+0.05+50.00%

15min DelayClose Jan 2 16:00 ET

0.20High0.15Low

Intraday

5D
Daily

News

Day One Biopharm Is Maintained at Buy by Jones Trading
Dow JonesDec 17, 2024 12:28 ET · Ratings
Day One Biopharmaceutical Analyst Ratings
BenzingaDec 17, 2024 12:17 ET · Ratings
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk
TipRanksDec 17, 2024 03:54 ET
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34
Moomoo NewsDec 16, 2024 16:31 ET · Ratings
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
PR NewswireDec 16, 2024 09:56 ET
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsDec 5, 2024 11:35 ET · Ratings

Comments

ApexTradeZ

Dec 25, 2024 10:20

What’s the Top Undervalued BioTech

$Humacyte (HUMA.US)$ $uniQure NV (QURE.US)$ $Aquestive Therapeutics (AQST.US)$ $IDEAYA Biosciences (IDYA.US)$ $Day One Biopharmaceuticals (DAWN.US)$
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you

IDKWTFIMDOING

Jul 25, 2024 13:43

$Day One Biopharmaceuticals (DAWN.US)$
https://www.tipranks.com/news/blurbs/strong-buy-rating-for-day-one-biopharmaceuticals-amid-strategic-partnership-and-promising-financial-health?futusource=news_stock_stockpagenews&ns_stock_id=80620831336770&src=2&utm_medium=referral&utm_source=moomoo.com&client_hour_clock=24&clientlang=2

Trytosaveabit

Jul 25, 2024 02:47

$Day One Biopharmaceuticals (DAWN.US)$ Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib
Benzinga· 01:54
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indications
OJEMDA (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II tria...

MARKET-TEST-DUMMY

Jun 19, 2024 15:39

turn around

$Day One Biopharmaceuticals (DAWN.US)$ we gonna see retraisement back to 18?

Trytosaveabit

Jun 12, 2024 06:34

Update

$XOMA Corp (XOMA.US)$ $Day One Biopharmaceuticals (DAWN.US)$ XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of Its Priority Review Voucher